Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study

被引:28
|
作者
Donadini, Marco P. [1 ,2 ]
Dentali, Francesco [1 ,2 ]
Pegoraro, Samuela [1 ,2 ]
Pomero, Fulvio [3 ]
Brignone, Chiara [3 ]
Guasti, Luigina [1 ,2 ]
Steidl, Luigi [1 ,2 ]
Ageno, Walter [1 ,2 ]
机构
[1] Univ Insubria, Dept Clin & Expt Med, Varese, Italy
[2] Azienda Sociosanit Terr Sette Laghi, Varese, Italy
[3] Osped S Croce & Carle, Dept Internal Med, Cuneo, Italy
关键词
low molecular weight heparin; recurrence; venous thromboembolism (VTE); distal deep vein thrombosis (DVT); calf DVT; ANTICOAGULANT-THERAPY; PULMONARY-EMBOLISM;
D O I
10.1177/1358863X17720531
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Isolated distal deep vein thrombosis (IDDVT) is a common clinical manifestation of venous thromboembolism (VTE). However, there are only scant and heterogeneous data available on the long-term risk of recurrent VTE after IDDVT, and the optimal therapeutic management remains uncertain. We carried out a retrospective cohort study of consecutive patients diagnosed with symptomatic IDDVT between 2004 and 2011, according to a predefined short-term treatment protocol (low molecular weight heparin (LMWH) for 4-6 weeks). The primary outcome was the occurrence of recurrent VTE. A total of 321 patients were enrolled. IDDVT was associated with a transient risk factor or cancer in 165 (51.4%) and 56 (17.4%) patients, respectively. LMWH was administered for 4-6 weeks to 280 patients (87.2%), who were included in the primary analysis. Overall, during a mean follow-up of 42.3 months, 42 patients (15%) developed recurrent VTE, which occurred as proximal DVT or PE in 21 cases. The recurrence rate of VTE per 100 patient-years was 3.5 in patients with transient risk factors, 7.2 in patients with unprovoked IDDVT, and 5.9 in patients with cancer (p=0.018). At multivariable analysis, unprovoked IDDVT and previous VTE were significantly associated with recurrent VTE (HR 2.16, 95% CI 1.12-4.16 and HR 1.97, 95% CI 1.01-3.86, respectively). In conclusion, the long-term risk of recurrent VTE after IDDVT treated for 4-6 weeks is not negligible, in particular in patients with unprovoked IDDVT or cancer. Further studies are needed to clarify whether a longer, but definite treatment duration effectively prevents these recurrences.
引用
收藏
页码:518 / 524
页数:7
相关论文
共 50 条
  • [21] Long-term treatment for venous thromboembolism
    Couturaud, F
    Kearon, C
    [J]. CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) : 302 - 308
  • [22] Long-term Treatment of Venous Thromboembolism
    Becattini, Cecilia
    Manina, Giorgia
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 384 - 392
  • [23] Venous thromboembolism: risk of recurrence and long-term anticoagulation
    Khalil, Leila
    Wong, Henna S.
    Keeling, David M.
    Desborough, Michael Jr
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2015, 76 (02) : 72 - 77
  • [24] Anatomical Predictors of Venous Thromboembolism Recurrence after Isolated Superficial Vein Thrombosis
    Galanaud, Jean-Philippe
    Sevestre, Marie-Antoinette
    Genty, Celine
    Kahn, Susan R.
    Pernod, Gilles
    Brisot, Dominique
    Quere, Isabelle
    Bosson, Jean-Luc
    [J]. BLOOD, 2015, 126 (23)
  • [26] Long-term consequences of deep vein thrombosis
    Leizorovicz, A
    [J]. HAEMOSTASIS, 1998, 28 : 1 - 7
  • [27] Long-term management of deep vein thrombosis
    Piovella, F
    Barone, M
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 : S117 - S122
  • [28] Long-term survival after venous thromboembolism: a cohort study among young women
    Reitter, S. E.
    Laczkovics, C.
    Waldhoer, T.
    Vutuc, C.
    Pabinger-Fasching, I
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1039 - 1039
  • [29] The use of rivaroxaban for short- and long-term treatment of venous thromboembolism
    Cohen, Alexander T.
    Dobromirski, Mark
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (06) : 1035 - 1043
  • [30] Incidence, clinical characteristics and long-term prognosis of postoperative symptomatic venous thromboembolism: a retrospective cohort study
    Takeda, Chikashi
    Yamashita, Yugo
    Takeuchi, Masato
    Yonekura, Hiroshi
    Dong, Li
    Hamada, Miho
    Hirotsu, Akiko
    Ono, Koh
    Kawakami, Koji
    Fukuda, Kazuhiko
    Morimoto, Takeshi
    Kimura, Takeshi
    Mizota, Toshiyuki
    [J]. BMJ OPEN, 2022, 12 (02):